Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

UCB SA divulges new DRD1 PAMs

July 12, 2022

Gritscience Biopharmaceuticals describes new casein kinase inhibitors

July 11, 2022

H. Lundbeck A/S discloses new NMDA glycine-site receptor modulators

July 11, 2022

GLP-1R agonist PF-1801 seen useful to treat polymyositis

July 8, 2022

Lamivudine has beneficial effects in mouse model of Down syndrome

July 7, 2022

Approved ALK inhibitors may provide pain relief

July 6, 2022

Novel dual RAGE/SERT inhibitor shows promise as treatment of AD with comorbid depression

July 6, 2022

Novel Alzheimer's disease model lacking interaction between FKBP51 and HSP90 generated

July 6, 2022

ACT-02 improves neurodegeneration in mouse model of PD

July 5, 2022

Mindset Pharma discovers 5-HT2A receptor agonists

July 5, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...